Drugs

PEER-REVIEWED FEATURE

Vutrisiran: AdisInsight Report

Key Points

- A transthyretin-directed RNAi that is being developed by Alnylam Pharmaceuticals, Inc. for the treatment of ATTR amyloidosis
- Received its first approval on 13 June 2022 in the USA
- Approved for use in the treatment of the polyneuropathy of hATTR amyloidosis in adults in the USA

Summary

Vutrisiran (AMVUTTRA™) is a subcutaneously administered transthyretin-directed small interfering ribonucleic acid (siRNA) therapeutic (also called RNA interference, or RNAi therapeutic) being developed by Alnylam Pharmaceuticals, Inc. for the treatment of amyloid transthyretin-mediated (ATTR) amyloidosis, including hereditary ATTR (hATTR) amyloidosis and wild-type ATTR (wtATTR) amyloidosis.

Vutrisiran was approved in June 2022 in the USA for the treatment of the polyneuropathy of hATTR amyloidosis in adults and received a positive opinion in the EU in July 2022 for the treatment of hATTR amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. Vutrisiran is also under regulatory review for the treatment of the polyneuropathy of hATTR amyloidosis in adults in Japan and Brazil.

Keam S.J. Drugs. 2022. https://doi.org/10.1007/s40265-022-01765-5